The 36th Annual Congress of the European Association of Nuclear Medicine (EANM) #EANM23 was held this year in Vienna from 9 to 13 September. It is a world-reference congress in nuclear medicine gathering clinical scientists, technologists, physicians, industry representatives and researchers.
Springer Healthcare IME hosted a symposium entitled “Preparing for the new era of neuroimaging for Alzheimer’s disease” on 10 September. The symposium was supported by an educational grant from Lilly and moderated by the AMYPAD Project Coordinator Frederik Barkhof (Amsterdam UMC,The Netherlands and University College London, UK). The learning objectives of the symposium were to:
- Explain the critical role of PET imaging in the new era of disease modification of Alzheimer’s disease
- Appraise the utility of current and emerging PET biomarkers in clinical practice
- Identify patterns from different PET tracers for a negative and positive AD brain and debate methods beyond binary amyloid PET interpretation.
The programme of the symposium included three talks:
- Role of PET imaging in the disease modification era of Alzheimer’s disease by Silvia Morbelli (University of Genoa, Italy)
- Advances in AD PET biomarkers by Alexander Drzezga (University of Cologne, Germany)
- PET tracers: Which, when, how, who? by Lyduine Collij (Lund University, Sweden)
During their respective presentations, Lyduine and Alexander shared some AMYPAD results.
For more information about #EANM23, visit https://eanm23.eanm.org/
We look forward to seeing you all at the #EANM24 in Hamburg, on October 19-23, 2024.
